Market-Moving Exclusives

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In...

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC). The biomarker-...

DeFi Development Corp (NASDAQ:DFDV) announced on Monday that it had purchased 172,670 Solana (CRYPTO: SOL/USD) at an average purchase price of $136.81, valued at approximately $23.6 million. This marks the company's 10th Solana purchase under its digital asset treasury strategy and its largest...

Inuvo, Inc. (NYSE:INUV) announced its financial results for the first quarter ended March 31, 2025, on Friday. Revenue climbed 57% year-over-year to $26.7 million, marking the highest revenue in the company’s history. The analyst consensus estimate was $23.7 million. A 61% increase within...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek the U.S. Food and Drug Administration (FDA) guidance on the Phase 3 clinical trial for AD04. The...

Mira Pharmaceuticals, Inc.’s (NASDAQ:MIRA) Board of Directors unanimously approved on Thursday the planned acquisition of SKNY Pharmaceuticals, Inc., following the completion of independent valuation reports on both companies. In March,  MIRA Pharmaceuticals signed a binding letter of...

On Thursday, Aduro Clean Technologies Inc. (NASDAQ:ADUR) announced the signing of a Memorandum of Understanding (MOU) with Cleanfarms Inc., a prominent Canadian organization specializing in agricultural waste management. This strategic, multi-phase collaboration will explore the technical and...

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced its partnership with Mint Labs Inc. d/b/a QMENTA, a medical imaging artificial intelligence company, to support its five upcoming Phase 2 trials of AL001 at Massachusetts General Hospital. QMENTA's cloud-based platform will manage and...

DeFi Development Corp (NASDAQ:DFDV), formerly Janover Inc., announced on Tuesday that it had purchased approximately 82,404.50 Solana (CRYPTO: SOL) tokens. Following this transaction, DeFi Development now holds approximately 400,091 SOL, valued at $58.5 million, including staking rewards. As of May...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist, on Tuesday. The U.S. Food and Drug Administration (FDA) required the study before initiating human dosing in the United States. The preclinical study showed no...

HF Foods Group Inc. (NASDAQ:HFFG), a distributor in the Asian specialty food sector, announced Tuesday that it is broadening its digital presence through the launch of a new online ordering platform tailored for restaurant staff. Over the next few months, HF Foods plans to introduce its new digital...

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative breast cancer (TNBC). The dual approach in the clinical trial is designed to evaluate LP-184 in...

On Thursday, Nvidia Corporation (NASDAQ:NVDA) CEO Jensen Huang told U.S. lawmakers that export restrictions on AI chips may be helping China's Huawei Technologies gain a competitive foothold in the global artificial intelligence race. What Happened: In a closed-door meeting with the House Foreign...

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. To date, 13 patients have received at least one dose of TTX-MC138 at four separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Two...

Silo Pharma, Inc. (NASDAQ:SILO) on Wednesday released results for its preclinical study evaluating SP-26. SP-26 is a ketamine-based injectable dissolvable polymer implant for chronic pain and fibromyalgia. If clinically successful, SP-26 could qualify for the FDA's streamlined 505(b)(2)...